320 related articles for article (PubMed ID: 22922860)
1. Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy.
Adhikary L; Acharya S
JNMA J Nepal Med Assoc; 2011; 51(183):133-6. PubMed ID: 22922860
[TBL] [Abstract][Full Text] [Related]
2. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis.
Charytan C; Qunibi W; Bailie GR;
Nephron Clin Pract; 2005; 100(3):c55-62. PubMed ID: 15824508
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
[TBL] [Abstract][Full Text] [Related]
4. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study.
Lindgren S; Wikman O; Befrits R; Blom H; Eriksson A; Grännö C; Ung KA; Hjortswang H; Lindgren A; Unge P
Scand J Gastroenterol; 2009; 44(7):838-45. PubMed ID: 19330567
[TBL] [Abstract][Full Text] [Related]
6. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
[TBL] [Abstract][Full Text] [Related]
7. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure.
Bolger AP; Bartlett FR; Penston HS; O'Leary J; Pollock N; Kaprielian R; Chapman CM
J Am Coll Cardiol; 2006 Sep; 48(6):1225-7. PubMed ID: 16979010
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
9. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
Van Wyck DB; Martens MG; Seid MH; Baker JB; Mangione A
Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600
[TBL] [Abstract][Full Text] [Related]
10. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iron sucrose v/s oral ferrous fumarate for treatment of anemia in pregnancy. A randomized controlled trial.
Bhavi SB; Jaju PB
BMC Pregnancy Childbirth; 2017 May; 17(1):137. PubMed ID: 28482869
[TBL] [Abstract][Full Text] [Related]
12. Changing patterns of anemia management in US hemodialysis patients.
Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
[TBL] [Abstract][Full Text] [Related]
13. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
Li H; Wang SX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
[TBL] [Abstract][Full Text] [Related]
14. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
15. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
17. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
Kotaki M; Uday K; Henriquez M; Blum S; Dave M
Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
[No Abstract] [Full Text] [Related]
19. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin.
Stoves J; Inglis H; Newstead CG
Nephrol Dial Transplant; 2001 May; 16(5):967-74. PubMed ID: 11328902
[TBL] [Abstract][Full Text] [Related]
20. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia.
Bregman DB; Morris D; Koch TA; He A; Goodnough LT
Am J Hematol; 2013 Feb; 88(2):97-101. PubMed ID: 23335357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]